Neuberg Diagnostics introduces blood test for Alzheimer’s screening in Chennai

Neuberg Diagnostics has introduced the Mispa i60 in Chennai for Alzheimer’s screening through a blood test. The test uses a blood sample to detect markers associated with Alzheimer’s disease and is positioned as an adjunct to clinical evaluation. It does not replace neuroimaging or cerebrospinal fluid testing.

The test measures p-tau and amyloid proteins, which are associated with Alzheimer’s disease. It enables detection of pathological changes before the onset of cognitive decline and supports differentiation between Alzheimer’s disease and other forms of dementia.

Dr Asma Bibi, Chief of Laboratory, Neuberg Diagnostics, said, “Alzheimer’s disease shares overlapping clinical features with other types of dementia, making diagnosis challenging. Studies have shown that a proportion of clinically diagnosed Alzheimer’s cases reveal non-Alzheimer’s pathology upon autopsy, further emphasizing the importance of accurate biomarker testing. This blood test can help differentiate Alzheimer’s from other dementia syndromes, ensuring that patients receive the correct diagnosis and appropriate treatment. We are excited about the possibilities this test brings for both clinicians and patients.”

Among patients tested at Neuberg’s OMR centre, 45 per cent showed an elevated tau-to-amyloid ratio, indicating Alzheimer’s pathology. These findings were supported through neurologist assessment and clinical evaluation.

The test provides a blood-based approach that complements cerebrospinal fluid testing and brain imaging. It enables early detection before cognitive symptoms, supports access to testing and offers an alternative to existing diagnostic methods.